Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | FSHR | P23945 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638312 | 0.84 | KMT2A (0.41) | L3MBTL1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12306235 | 0.79 | FFAR3 (0.36) | TSHRFSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL28111563 | 0.79 | SMN1; SMN2 (0.38) | L3MBTL1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL16797890 | 0.79 | USP2 (0.37) | GRM5TSHRL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL12306234 | 0.78 | TSHR (0.36) | TSHRFSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL25269622 | 0.74 | FFAR3 (0.44) | GRM5TSHRL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL7018317 | 0.74 | FFAR3 (0.44) | GRM5TSHRL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL25268918 | 0.74 | FFAR3 (0.44) | GRM5TSHRL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL30453762 | 0.72 | HPGD (0.39) | ACACBL3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL30453434 | 0.72 | HPGD (0.39) | ACACBL3MBTL1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | HSD11B1 3294/4885GRM5 2643/4885ACACB 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.